Main description:

This volume, a state-of-the-art review of early phase clinical trials for cancer immunotherapy, discusses biomarker selection, combinatorial strategies and their safety or toxicity, determination of Phase 2 dosing, endpoints in the setting of radiographic pseudoprogression, histology selection, and novel immunotherapeutics as they relate to early phase cancer immunotherapy.

Contents:

Chapter 1 Primer on Cancer Immunotherapy and the Targeting of Native Proteins.- Chapter 2 Pharmacokinetics and Pharmacodynamics of Immunotherapy.- Chapter 3 Immunotherapeutic Biomarkers and Selection Strategies.- Chapter 4 Radiographic Evaluation of Immunotherapy.- Chapter 5 Cellular Therapy.- Chapter 6 Combinatorial Checkpoint Blockade Immunotherapy and Radiation.- Chapter 7 Early Phase Cancer Immunotherapy.- Chapter 8 Immune Checkpoint Combinations with Inflammatory Pathway Modulators.- Chapter 9 Combinations of Genomically and Immune-Targeted Therapies in Early-Phase Clinical Trials.- Chapter 10 Thoracic Immunotherapy.